Letrozol Stada

Letrozole, the active ingredient in Letrozol Stada, is an aromatase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of hormone‑receptor positive breast cancer in postmenopausal women, both in the adjuvant and metastatic settings. GNH USA supplies Letrozol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Letrozol Stada is an aromatase inhibitor used in the endocrine therapy of breast cancer. - Early‑stage hormone‑receptor positive breast cancer: reduces the risk of disease recurrence when given as adjuvant therapy. - Metastatic hormone‑receptor positive breast cancer: helps control tumor growth and prolongs survival in postmenopausal patients. - Hormone‑receptor positive breast cancer after surgery: used as part of postoperative systemic treatment to lower estrogen‑driven cancer progression.

Letrozol Stada may cause a range of adverse reactions.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: aching or stiffness in limbs. - Fatigue: persistent tiredness not relieved by rest. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated liver enzymes, or hepatic failure. - Bone fractures: increased risk of osteoporosis‑related fractures. - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Severe allergic reactions: rash, swelling, or anaphylaxis.

Before initiating Letrozol Stada, several safety considerations are recommended. - Monitor bone health: assess baseline bone mineral density and consider calcium/vitamin D supplementation. - Assess liver function: obtain baseline liver enzymes and repeat periodically. - Evaluate cardiovascular risk: screen for history of thrombosis or clotting disorders. - Contraindicated in pregnancy: avoid use in women who are or may become pregnant. - Use caution with concomitant estrogen therapy: may reduce drug efficacy. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Letrozol Stada can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Estrogen replacement therapy: antagonizes aromatase inhibition and diminishes therapeutic effect. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower plasma concentrations of letrozole.

Moderate Interactions (Monitor Closely): - Tamoxifen: concurrent use may interfere with hormonal pathways; monitor clinical response. - Warfarin: letrozole may alter INR; check coagulation status regularly. - Certain SSRIs (e.g., fluoxetine): may affect metabolism; observe for increased side effects.